IBM Watson Health and EBSCO Information Services have formed a strategic partnership to create a combined solution called DynaMed and Micromedex with Watson.
The partnership is aimed at enhancing clinical decision support (CDS) and operations for healthcare providers and health systems.
The combined solution collects drug and disease content into a single source to help inform clinical decisions, improving clinical decision-making.
IBM Watson Health chief health officer vice-president Anil Jain said: “Research shows that healthcare provider confidence in clinical decision support comes from knowing the evidence-based methodologies that helped build the content foundation.
“When clinicians are confident that their clinical decision support is drawing recommendations from accurate and timely information, they are more likely to use the technology to support their care decisions.”
EBSCO’s DynaMed provides peer-reviewed clinical content that includes systemic reviews literature across 28 specialties.
IBM Micromedex is an online reference database for medication information, which is used by over 4,500 hospitals and other health systems worldwide.
IBM Watson Health noted that DynaMed and Micromedex with Watson will be available for adoption in April this year.
IBM Watson Health IBM Micromedex Solutions general manager Todd Nolen said: “When it comes to clinical decision support, content is king. Nearly nine out of ten physicians in the US currently implement electronic health record technology.
“We believe DynaMed and Micromedex with Watson can deliver value and innovation to healthcare organisations, to help enable rapid access to high-quality medical evidence that is essential for clinicians as they work to provide safe and effective patient care within their clinical workflow.”
IBM and EBSCO’s individual solutions will continue to be available to healthcare organisations in search of more specialised resources
Last month, IBM Watson Health launched its latest Cloud-based technology, IBM Study Advance. It is designed to reduce the cost and time associated with clinical trials.